Hanmi Science008930.KS

關於Hanmi Science

Hanmi Science is the holding company of the Hanmi pharmaceutical group, created when the founding Lim family reorganized the business into a two-tier structure. Its central asset is a controlling stake in Hanmi Pharmaceutical, and the umbrella also covers affiliates such as Hanmi Fine Chemical in active ingredients and units in packaging and pharmacy automation equipment. Operating income at the holding level comes from subsidiary dividends, brand royalties, and its own distribution activities rather than drug discovery, which resides at the operating company. The entity is the vehicle through which the family exercises control over the group.

The stock trades as a leveraged proxy for Hanmi Pharmaceutical, carrying the customary Korean holding-company discount and the sum-of-the-parts arithmetic that comes with it. Because the founding family's control runs through this entity, ownership questions, from inheritance taxes to stake sales and boardroom alignment among family members, land here first, and shifts in the shareholder register can move the stock independently of pharmaceutical fundamentals. Dividends received from the operating company set the holding company's own payout capacity. The two-tier listing invites constant comparison of where value accrues along the chain.

Hanmi Science emerged from the July 2010 division of the original Hanmi Pharmaceutical, in which the historic listed entity became an investment holding company and drug operations moved to a newly listed subsidiary; it took the Hanmi Science name in 2012. Founder Lim Sung-ki designed the structure to secure family control and organize the affiliates, which came to include Hanmi Fine Chemical in active ingredients, the pharmacy-automation equipment maker JVM, brought into the group in 2016, and healthcare distribution ventures. After the founder's death in 2020, his widow Song Young-sook assumed the chairmanship, and family shareholdings became the fulcrum of group control.

Hanmi Science generates revenue beyond passive dividends. It charges affiliates royalties for the Hanmi brand, provides shared corporate services, and oversees distribution businesses serving pharmacies and clinics. Subsidiary JVM sells automated drug-dispensing and packaging systems to pharmacies in Korea and abroad, a niche equipment business with its own export economics, while Hanmi Fine Chemical supplies active ingredients to drugmakers. Still, the controlling stake in Hanmi Pharmaceutical dwarfs these operations, so the parent's fortunes track the drugmaker's research and licensing outcomes. Its competitive meaning lies in control: whoever holds sway here directs one of Korea's most research-intensive pharmaceutical groups.

公司簡介由LineVest編輯部撰寫。屬新聞報導，非投資建議。 委託撰寫Hanmi Science的DART完整報告 →